Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified saltinducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21
Introduction
Ovarian carcinoma represents one of the most insidious and aggressive cancers and is also the most lethal gynecological malignancy in the United States and Taiwan. The high mortality rate of ovarian cancer is a consequence of the fact that 70-75% of women with this disease are diagnosed with stage III or IV disease (Runnebaum and Stickeler, 2001 ). Thus, discovery of new relevant biomarkers to increase specificity or sensitivity for early diagnosis and prognosis of ovarian cancer is an important and urgent need. Besides their potential clinical use for diagnosis and prognosis of this disease, study of their pathological functions in tumorigenesis or in tumor malignancy is not only provide molecule-basis understanding in fundamental cancer biology, but also may identify potential signaling mediators of the biomarkers in cancer cells for targeting therapy in future.
One promising approach in this field is to study the immune responses to cancer and identify more tumor-associated antigens (TAAs) for clinical applications. The presence of humoral response to TAAs has been well demonstrated in patients with various cancers. The responses are frequently mounted against tumor cells expressing altered or abnormally high levels of normal self-antigens with inappropriate timing (Brewer et al., 2009) , cellular compartmentalization (Chang et al., 2006) or tissue expression (Old, 2008 ) that result in increased immunogenicity. Therefore, high levels of tumor-associated autoantibodies can be also observed in some cancer patients throughout their disease progressions (Gagnon et al., 2008) , and some of them are associated with their disease outcomes (Reuschenbach et al., 2009) . Currently, over 100 immunogenic TAAs have been reported in patients with a variety of cancers; however, few of them are associated with ovarian cancer, including CA125 (Reuschenbach et al., 2009; Taylor et al., 2009) .
CA125 is the best-characterized tumor marker for advanced epithelial ovarian cancer. CA125 is a type I transmembrane protein expressed on the cell surface (O'Brien et al., 2002) . Its soluble proteolytic fragment can be released into the blood stream. Thus, serum CA125 has been studied intensively as a potential biomarker for diagnosis of epithelial ovarian cancer or to monitor disease recurrence after therapy (Baron et al., 2005; Rosenthal et al., 2006) . However, elevated CA125 expressions are not only observed in >80% of patients with advanced epithelial ovarian cancer, but are also found in various physiological or pathological conditions (Cannistra, 2004) . In this study, we used serological screening of a phage library with malignant ascitic antibodies and identified salt-inducible kinase 3 (SIK3) as a novel TAA for ovarian cancers.
SIKs have their kinase domain sequences closely homologous to AMP-activated protein kinase (AMPK) (Lizcano et al., 2004; Bright et al., 2009) , and may have a role in steroidogenesis, adipogenesis or regulation of tumor malignancy. Three isoforms in the SIK family have been identified so far, namely, SIK1 (SNF1LK), SIK2 (QIK or SNF1LK2) and SIK3 (KIAA0999 or QSK) Lizcano et al., 2004) . SIK1 is an important regulator for steroidogenic gene expression, and can be activated by increased intracellular sodium leading to stimulation of Na þ /K þ -ATPase activity and activation of calmodulin kinase (Sjostrom et al., 2007) . In addition, it is also reported to participate in a negative feedback program initiated by transforming growth factor-b (Kowanetz et al., 2008) . Loss of SIK1 expression facilitated lung metastatic spread in mice and was closely correlated with the development of distal metastasis in human breast cancers (Cheng et al., 2009) . SIK2, highly expressed in the adipose tissue , is found to inhibit cAMP-response element binding protein-mediated gene expression by phosphorylating transducer of regulated CREB activity 2 (TORC2), thus sequestering TORC2 in the cytoplasm, and preventing cAMP-response element binding proteinmediated gene transcription (Screaton et al., 2004) . Insulin receptor substrate-1 is a downstream substrates of SIK2 (Horike et al., 2003) , suggesting that SIK2 has a role in the insulin regulation of adipose tissues. As compared with SIK1 and SIK2, the biological functions of SIK3 are entirely obscure, particularly in cancers. The knockdown of Drosophila CG15072 (homologous to mammalian SIK3) resulted in impairment of the LKB1-regulated apicalbasal polarity in retinal photoreceptor cells (Amin et al., 2009) , showing that this orthologue of SIK3 is probably one of mediators of the LKB1 effect on the cells. Since loss of the cell polarity is closely associated with development of the epithelial-mesenchymal transition of epithelial-derived cancer cells during tumor metastasis (Guarino, 2007) , it may represent a key mechanism by which LKB1 and SIK3 are related to cancers. Here, we report that SIK3 is an ovarian TAA. Increasing expression of SIK3 promoted G1/S cell cycle progression via activation of c-Src-phosphoinositide-3-kinase (PI3K) linkage to downregulate p21
Waf/Cip1 and led to tumorigenesis in mice. As SIK3 is highly and preferentially expressed in ovarian tumors but not in adenomyosis and leiomyoma, it can be a potential diagnostic marker for ovarian cancers.
Results
Identification of KIAA0999 gene product, SIK3, as the target of the CA502 ascitic antibody Although tumor-associated antibodies have been found in the ascitic fluids of ovarian cancer patients (Giancotti et al., 1990) , only a few ovarian TAAs were identified. In this study, the ascitic tumor cells of 12 patients were first purified with Ficoll-Percoll gradient centrifugation, lyzed and immunoblotted with their ascitic autoantibodies as described previously (Chang et al., 2006) . The ascitic antibodies of patient CA502 were highly immunoreactive to a major protein band with an approximate molecular mass of 150 kDa in the autologous tumor lysates (Supplementary Figure 1A) . To identify the target of the autoantibody, a 7-mer random peptide phage library was screened as illustrated in Figure 1a . The library was pre-absorbed with the total immunoglobulin G (IgG) mix of 10 healthy donors to remove the phages recognized by the IgG. Subsequently, the resultant library was applied onto enzyme-linked immunosorbent assay wells pre-coated with the CA502 ascitic IgG. After four biopanning cycles, the bound phages were eluted and allowed to infect their Escherichia coli host cells. Direct sequence analyses of 15 random clones revealed 3 residues highly conserved in the displayed peptides, x-Pro-His-x-Tyr-x-x (x: any residue) (Supplementary Table 1) . By searching the NCBI protein database, we found that human KIAA0999 (accession number: AB23216) and CRBN genes (access number: NM_016302) could encode for proteins containing the conserved residues highlighted with grey background (Pro-Pro-His-Gly-Tyr-Ala-His and Asn-Pro-His-Gly-Tyr-Val-His peptide sequences in KIAA0999 and CRBN proteins, respectively) and might be the putative targets of the CA502 autoantibodies. However, no immunoreactive protein band with an approximate molecular mass of 48.6 kDa, suspected to be CRBN, was found in the CA502 tumor lysates (Supplementary Figure 1A) . For not to rule out this possibility easily, ovarian normal epithelial and cancer cells, including CA502 tumor cells, were carefully examined for CRBN expression by probing with its specific antibody in western blotting analysis (Supplementary Figure 1B) . Using the CRBN recombinant protein as SIK3 is involved in ovarian tumorigenesis S Charoenfuprasert et al a control, the experiment clearly revealed that CRBN was undetected in those cells. Additionally, the same conclusion was also obtained from immunohistochemical (IHC) study in 38 ovarian tumor samples (Supplementary Figure 1C) , suggesting that CRBN is lowly expressed in ovarian cancer cells and tissues.
To examine whether the protein encoded by KIAA0999 might be the target of the CA502 antibodies, the putative 3 0 -coding sequence of the KIAA0999 gene including the consensus sequence was amplified by PCR and expressed as a C-terminal KIAA0999 recombinant protein tagged with the Myc sequence (Myc-CT-0999) in HeLa cells. This polypeptide was specifically recognized by the CA502 antibody (Figure 1b) . Deletion of the 7-mer conserved sequence in the polypeptide, which shares a six-residue identity with the phage-displayed peptide (Supplementary Table 1) , by site-directed mutagenesis ablated the antibody recognition (Figure 1c ), confirming that this protein is the target of the CA502 antibody and that the 7-mer peptide, Pro-Pro-His-Gly-Tyr-Ala-His, is its major immunogenic epitope. Recently, the KIAA0999 gene product was named SIK3 that belongs to the AMPK-related kinase family .
Expression of SIK3 promotes cell growth and tumorigenesis in animals Four ovarian cancer cell lines were tested for correlation between the expression levels of SIK3 and the corresponding cell growth. MTT assays were performed to measure the growth, showing that SK-OV3 and TOV-112D cells grew faster than the other two cell lines, OVCAR3 and OC-109 cells (Supplementary Figure 2A) . Coincidently, northern blotting experiments using a A phage display peptide library was pre-absorbed with healthy control sera, followed by incubation with immobilized CA502 ascitic antibody. After removal of the unbound phages, the bound M13 phages were eluted, propagated and re-absorbed with the healthy control sera. Four panning cycles were performed. Fifteen bound phage clones were randomly selected and sequenced. The peptide sequences of individual clones are listed in Supplementary Table 1. (b) The putative KIAA0999 gene product is the target of the CA502 antibody. The 3 0 -coding region of the KIAA0999 gene containing the consensus peptide sequence of the bound phages was fused with the Myc tag sequence (Myc-CT-0999), transfected, and used to encode a 42 kDa protein in HeLa cells. Western blot analyses of the lysates were performed using purified CA502 ascitic IgG and 9E10 antibody specific to the Myc tag, as indicated. (c) Confirmation of the displayed peptide as the major immunogenic epitope. The Myc-del-CT-0999 gene lacking the 7-mer conserved sequence, PPHGYAH, which shares a six-residue identity with the phage-displayed peptide (Supplementary Table 1), was transfected into HeLa cells. After cell lysis, the lysates were resolved in a 10% sodium dodecyl sulfate-containing polyacrylamide gel and immunoblotted with the CA502 antibody. The same blot was re-probed with the 9E10 antibody to show equal expression of the wild-type and deletion mutant.
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S Charoenfuprasert et al P-labeled antisense SIK3 probe revealed that a 4.6 kb gene was the major transcript, which was highly abundant in high-grade SK-OV3 and TOV-112D cells as compared with that in low-grade OVCAR3 and OC-109 cells (Supplementary Figure 2B) . Using an antibody specific to the C-terminus of SIK3, western blot analysis indicated that a 150 kDa polypeptide was the major corresponding protein encoded by this transcript and highly expressed in the fast-growing SK-OV3 and TOV-112D cells (Supplementary Figure 2C) . These results were further verified by in vitro transcription/ translation-coupled reactions using the full-length SIK3 or KIAA0999 gene as the DNA template (data not shown) and also by SIK3 gene-specific knockdown experiments (Figure 2A ).
To examine whether SIK3 was involved in the promotion of cell proliferation, OVCAR3 cells stably overexpressing SIK3 or SK-OV3 cells with attenuated levels of SIK3 were established. Two clones of each transfectant were randomly chosen, and their SIK3 expression levels were confirmed by reverse transcriptase-PCR and western blot analyses (Figure 2A) . Results from the MTT assays indicate that SIK3 is a positive regulator of cell growth, showing that its expression status is consistent with the corresponding growth of transfectants ( Figure 2B ). Furthermore, clonogenic experiments using different numbers of OVCAR3 cells stably overexpressing SIK3 (OVCAR3/ov-21) seeded onto six-well plates to allow cell propagation up to 9 days consistently demonstrated that the SIK3 transfectants evidently grew faster in a dose-dependent manner and formed larger colonies than control cells ( Figure 2C ).
To further validate its role in the promotion of cell growth, we subcutaneously inoculated stably transfected SK-OV3 cells with decreased SIK3 expression ( Figure 3a ; black arrow) or OVCAR3 cells with SK-OV3 or OVCAR3 cells were transfected with the SIK3-specific small hairpin RNA (shRNA) to attenuate the SIK3 expression or with the pcDNA-SIK3 plasmid to elevate its expression. The stable transfectants were obtained by G418 (400 mg/ml) treatment. After limiting-dilution, two clones of each transfectants were randomly chosen. The SIK3 expression level of these cells was determined by reverse transcriptase (RT)-PCR (upper) and western blot (lower). The control cells (VC) were established in the same manner by transfection with their corresponding vectors. b-Actin served as a loading control. (B) Cell growth of the stable transfectants. Cells (2 Â 10 4 per well) were seeded onto 24-well plates and incubated for 24, 48, 72 or 96 h as indicated. The cell growth of transfectants was measured by a standard MTT assay. Data are the mean±s.d. of three experiments and represented as fold increases in the cell growth of individual transfectants at 24 h. The growth differences between individual transfectant clones with attenuated SIK3 expression or between individual transfectant clones overexpressing SIK3 and their corresponding controls were statistically analyzed with t-test at 96 h time point. ***Po0.001 for both SIK3 transfectant clones in each experiment. (C) Clonogenic assays. The SIK3 stable transfectants (black bar; ') and control cells (white bar; &) were seeded onto six-well culture plates at 250, 500 or 1000 cells per well in triplicate. Cells were maintained in culture for 9 days to let the viable cells propagate to sizable colonies. After wash, the cells were stained with methylene blue and photographed under a microscopy. One representative pair from experiment (a) 250 cells, (b) 500 cells or (c) 1000 cells seeded initially is shown in the top. After cell lysis, the concentrations of released dye were determined using an enzyme-linked immunosorbent assay (ELISA) plate reader by measuring the absorbance at 550 nm. Quantitative data from the experiments are presented in the histograms, and the growth differences between the SIK3 transfectants and their controls in the experiments were analyzed by t-test. Figure 3b ; white arrow) in the right side of the dorsal flanks of six mice. To avoid individual variations in mice, the corresponding control cells were subcutaneously inoculated in the left side of the dorsal flanks of the same mice. The results clearly show that knockdown of SIK3 expression completely abolished the tumorigenic potency of SK-OV3 cells in mice. Accordingly, overexpression of SIK3 bestowed survival advantages to OVCAR3 cells so that they could grow in mice. Collectively, our data strongly support the tumorigenic role of SIK3 in ovarian cancers.
S Charoenfuprasert et al increased SIK3 expression (
Promotion of cell cycle progression by SIK3
To further explore the mechanisms underlying SIK3-mediated tumorigenesis, the cell cycle statuses of SIK3-transfected cells were examined. The stable transfectants were starved to synchronize their cell cycles, and then stimulated with fresh serum for 6 h. Flow cytometric analyses in Figure 4a revealed that the attenuation of SIK3 expression in SK-OV3 cells significantly accumulated the cells in the G1 phase from 49 to 74% on average. The cell population in the S phase was reduced from 33 to 8%, whereas the percentage of G2/M cells was not altered. Consistently, increasing expression of SIK3 in OVCAR3 cells markedly enhanced the G1/S transition, showing that its overexpression could significantly decrease the G1 cell population and increase the S phase cells. Moreover, facilitation of the G1/S progression by SIK3 was also seen in transient transfectants in a dose-dependent manner (Figure 4b ). Western blot analyses in Figure 4c showed that SIK3 greatly affected the gene expression of p21 Waf/Cip1 , cyclin D4 and cyclin E, as well as partially modulated p27 Kip and cyclin D1. In contrast, there was no significant change in the cyclin D3 expression, and no cyclin D2 protein was detected in both cell lines (data not shown). Conclusively, SIK3 delivering its tumorigenic potency to ovarian cancer cells is mainly through promotion of G1/S progression processes.
SIK3-mediated downregulation of p21
Waf/Cip1 is through c-Src activation In our preliminary study, increasing expression of p21
Waf/Cip1 was sufficient to induce G1/S arrest in SK-OV3 cells (data not shown). This result agrees with previous studies (Deng et al., 1995) , suggesting that it is also a key effector of SIK3-induced cell cycle regulation. To dissect which downstream signaling pathway might be responsible for SIK3-mediated downregulation of p21 Waf/Cip1 , various pharmacological kinase inhibitors were utilized for rescue of this effect. In Figure 5a , PP2, a c-Src inhibitor, fully rescued p21
Waf/Cip1 expression in SIK3-transfected OVCAR3 cells. In contrast, LY294002 for PI3K, staurosporine for broad-spectrum kinases and rapamycin for mechanistic target of rapamycin-mediated S6 kinase accounted for 70, 55 and 30% of the rescue, respectively. Thus, these data suggest that c-Src may be the major downstream signaling mediator ) were subcutaneously injected into the right side of the dorsal flanks of six mice. Simultaneously, their corresponding control cells were injected into the left side of the same mice. The tumor volumes of the individual mice were measured weekly (upper left of (a) for SK-OV3 and of (b) for OVCAR3 transfectants). The differences between SIK3 transfectants and their corresponding controls in the averages of the tumor sizes of paired groups were statistically determined by t-test analyses after mice killing (upper right of both panels). '*' and '**' indicate Po0.05 and Po0.01, respectively. In the bottom panels, the sides inoculated with transfectants that stably attenuated SIK3 expression (sh-SIK3) are indicated with black arrows, and the sides inoculated with transfectants stably overexpressing SIK3 (ov-SIK3) are marked with white arrows.
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S Charoenfuprasert et al responsible for SIK3 action. To verify the hypothesis, the kinase activity of c-Src in transfectants with decreasing (sh-SIK3) or increasing (ov-SIK3) expression of SIK3 was closely examined. The results show that SIK3 positively regulated the c-Src activity in a dosedependent manner (Figure 5b ). Furthermore, experiments using various doses of PP2 to block the c-Src activity in SIK3-transfected OVCAR3 cells showed that despite which concentrations in use, this inhibitor significantly impaired the SIK3-induced cell growth 48 and 72 h post-treatments (Figure 5c ). The IHC study in Figure 6 consistently supported the in vitro and in vivo observations, demonstrating that c-Src was coexpressed in 85% of the ovarian cancer samples stained positive for SIK3. Together, all data indicate that increasing c-Src activity is a key mechanism underlying SIK3 overexpression responsible for promotion of cell proliferation in ovarian cancer cells and close association with tumorigenesis in mice and in patients with ovarian cancers.
On the other hand, modulation of the c-Src protein level by either elevation or knockdown of its gene reversely regulated p21
Waf/Cip1 expression (Figure 7a ), indicating that c-Src is an upstream signaling regulator of the p21
Waf/Cip1 gene. Thus, SIK3 may exert its biological action by downregulation of p21
Waf/Cip1 via c-Src (Figures 4b and c) . In Figure 7b , in the absence of SIK3, decreasing expression of p21
Waf/Cip1 significantly relieved the G1/S arrest and elevated the percentage of S-phase cell populations in a dosedependent manner. In previous studies, c-Src is a pivotal promoter for cell proliferation responses through either activation of mitogen-activated protein/extracellular signal-regulated kinase or PI3K in different cancer cells (Cantley, 2002) . We further characterized which pathway underlying c-Src activation in ovarian cancer cells was responsible for the p21 Waf/Cip1 downregulation event. Experiments pretreating OVCAR3 cells with PD98059, LY294002 or PP2 and followed by c-Src transfection indicated that PI3K was the immediate downstream signaling molecule of c-Src (Figure 7c) . Collectively, the activation of the Src-PI3K signaling cascade is a key event during the promotion of G1/S progression by SIK3 via regulation of the p21
Waf/Cip1 gene.
Preferential expression of SIK3 in ovarian cancer
To determine whether the overexpression of SIK3 was associated with ovarian cancer, the serial sections of ovarian cancers and gynecological benign tumors, such as adenomyosis and leiomyoma as well as histologically normal ovarian tissues were examined by IHC studies (Figures 8 and 9 ). Approximately 55% of the ovarian tumor samples were stained positive for SIK3 (Table 1) , and showed that SIK3 was primarily located in the cytoplasm of the tumor cells (Figure 8c ). No SIK3 immunoreactivity was detected in normal ovarian tissues, including embedded fallopian tubes (Figures 8a and b) and leiomyoma (Figure 9c ). Additionally, only 10% (2 out of 20) of adenomyosis samples were weakly stained positive for SIK3 (Supplementary Figure 3) . In contrast, CA125 antigen was typically expressed on the cell surface of ovarian tumor cells (Figure 8d ) and in 80% of adenomyosis samples we have examined so far 4 cells per well) were seeded onto 24-well plates in triplicate 24 h before treatments, and then the cells were treated with increasing doses of PP2 (0.1, 0.5 and 2.5 mM) or with control vehicle for designed time courses. OVCAR3 cells stably transfected with control vector (OVCAR3/VC) were used as controls. The cell growth of transfectants was determined by MTT assays. Data are the mean±s.d. of three experiments and represented as fold increases in the cell growth of transfectants at the start time point of the treatments. The statistical significance in the growth difference was determined by t-test. '*', '**', and '***' indicate Po0.05, o0.01 and o0.001, respectively.
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( Figure 9b ; Table 1 ). Using SIK3 to predict ovarian cancer in our cases, we obtained a sensitivity of 53% and a specificity of 97%, whereas CA125 analysis gave a 79% sensitivity and a 65% specificity to ovarian cancer. Moreover, SIK3 was also preferentially overexpressed in the serous subtype and in the late stage of ovarian cancers (P%0.001) (Table 1) . Thus, data in the IHC study further support the results obtained from the in vitro and animal studies, indicating that SIK3 expression is associated with development of ovarian cancers.
Discussion
Using malignant ascitic antibodies to screen for tumorassociated peptides in a 7-mer random peptide phage library, we identified SIK3 as an ovarian cancer TAA. Its overexpression in tumor cells results in stimulation of cell proliferation by accelerating the G1/S progression processes. Consistently, the SIK3 overexpression phenomenon is frequently found in ovarian cancer but not associated with adenomyosis and leiomyoma. Approximately 55% of ovarian cancer samples stained positive for SIK3 belong to the serous subtype and late stages of patients, suggesting its role in tumor malignancy. Furthermore, we demonstrated the oncogenic potency of SIK3 in ovarian cancer cells using clonogenic assays and in xenografted tumors using NOD-SCID mice, showing that its expression status in the cancer cells is sufficient to affect cell proliferation and tumor growth. The molecular mechanism underlying its oncogenic potency is mediated by manipulation of cell cycle regulatory proteins, in particular for regulation of p21
Waf/Cip1 gene expression, to facilitate G1/S transitional progression via activation of the Src-PI3K signaling cascade. Knockdown of SIK3 expression resulted in G1/S arrest. Depletion of c-Src abolished SIK3-indcued cell proliferation; on the other hand, attenuation of p21
Waf/Cip1 expression markedly rescued the G1/S arrest caused by SIK3 depletion in SK-OV3 cells, suggesting that c-Src and p21
Waf/Cip1 are signaling mediators of the SIK3 effect on cell growth. Similarly, more recent one interesting observation reported by Ahmed et al. (2010) demonstrated that depletion of another SIK family member, SIK2, caused failure in centrosome separation in mitosis and delayed G1/S transition resulting in the growth suppression in SK-OV3 cells via inactivation of AKT. Moreover, they also showed the molecular profile of SIK2 depletion in mice and correlated high expression of SIK2 with poor survival of patients with highgrade serous ovarian cancers. On the basis of their functional similarity on cell cycle regulation, overexpression of SIK2 and SIK3 apparently bestows a great survival benefit to ovarian tumor cells. Therefore, depletion of individual or both proteins is a potential therapeutic approach for ovarian cancer treatment.
SIK3 belongs to the AMPK-related kinase family because of their sequence homolog with the protein kinase domain of AMPK and can be phosporylated by a tumor-suppressor kinase LKB1 (Bright et al., 2009) . Mutations in its gene result in a hereditary disorder termed Peutz-Jeghers syndrome (PJS). LKB1, has been well-documented to be a master upstream activator of AMPK and AMPK-related kinase, activates SIK1, SIK2 and SIK3 by phosphorylation of Thr182, Thr175 and Thr163 residues at their activation loops, respectively (Lizcano et al., 2004) . Moreover, the work of Katoh et al. (2006) showed the cytoplasmic retention of TORC2 could only be found in the LKB1-deficient HeLa cells when LKB1 was co-transfected with SIK3 into the cell. On the other hand, one point mutation of threonine to glutamate at the 163th residue in SIK3 (T163E) led to constitutive activation of SIK3, which was showed to be sufficient to cause the nuclear export of TORC2 and inactivate cAMP-response element 
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S Charoenfuprasert et al binding protein-dependent transcriptional activation in the LKB1-deficient cells, suggesting that the phosphorylation of Thr163 by LKB1 is required for SIK3 biological functions. In contrast, the equivalent residue substitution in SIK1 and SIK2 did not display the same effect. Thus, the level of LKB1 protein and its gene integrity become critical issues and are needed for a more intensive study in patients with ovarian cancers because we showed SIK3 highly expressed in the disease. Another important finding in this study is that the c-Src activity was indispensable for the SIK3 effect on promotion of cell growth. Blockade of the activity ablated SIK3-induced cell proliferation in OVCAR3 cells overexpressing SIK3. Intriguingly, c-Src is recently found to be progressively activated during the course of cell transformation in human papilloma virus (HPV)-immortalized cells and controlled the AMPK-regulated protein synthesis (Mizrachy-Schwartz et al., 2007) . The c-Src action is considered to optimize energy-consuming mechanisms that re-direct cellular processes to enhance cell growth. In our work, overexpression of SIK3 in ovarian cancer cells is expected to phosphorylate TORC2 leading to its protein degradation in the cytoplasm and attenuation of cAMP-response element binding protein-mediated gluconeogenesis. The consequence of this event should lower the cellular adenosine triphosphate in the cells. Whether it represents a mechanism by which the cells reduce their cell sizes and protein translation to provide Waf/Cip1 expression promoted the G1/S progression in SIK3-knockdown transfectants. SK-OV3 cells (1 Â 10 5 cells per well) were seeded onto six-well plates, incubated for 24 h, and transfected with SIK3-interfering shRNA plasmid or co-transfected the plasmid with different amounts of the p21
Waf/Cip1 shRNA construct as indicated in the upper panel. Western blotting analyses of the transfectants were performed by probing with antibody specific to p21
Waf/Cip1 , SIK3 or b-actin 24 h after transfection. The cell cycle statuses of the transfectants were determined by flow cytometric analyses using PI staining. Data were acquired from the experiments using a BD FACScaliber cytometer and the percentage of cells in each cell cycle stage was determined using ModFit software. One representative set of the observations is shown in the middle panel. Quantitative data are presented in the histograms (bottom panel). The differences between p21
Waf/Cip1 individual transfectants and vector control cells in the percentages of cells were statistically analyzed by t-test. '*' and '***' indicate Po0.05 and Po0.001, respectively. (c) p21
Waf/Cip1 expression controlled by the Src-PI3K signaling pathway. OVCAR3 cells were pretreated with PD98059 (PD), LY294002 (LY), PP2, or control vehicle (C), 2 h before transfection of the pcDNA-Src (ov-Src) plasmid. After 24-h transfection, the transfectants were lyzed, electrophorized, and immunoblotted with antibody against p21
Waf/Cip1 or c-Src. b-Actin served as a loading control.
SIK3 is involved in ovarian tumorigenesis S Charoenfuprasert et al energy required for cell proliferation and survival, proposed by Mizrachy-Schwartz's group, remains to be closely examined in future.
The different kinase activation of SIK3 and SIK1 may contribute to their distinct biological functions on tumorigenesis. SIK1 was identified as an upstream regulator of p53 in a kinome-wide loss-of-function screen, showing that SIK1-coupled LKB1 to regulate p53-dependent anoikis and suppress metastatic spread of disseminated cells as micro-metastases in the lung (Cheng et al., 2009 ). In addition, SIK1 is also reported to participate in other biological activities (Okamoto et al., 2004; Berdeaux et al., 2007; Sjostrom et al., 2007; Kowanetz et al., 2008) , including regulation of active sodium transport in response to sodium stress as well as induction of steroidogenic gene expression. Intriguingly, stanniocalcin 1 (STC1), a glycoprotein hormone involved in the regulation of calcium and phosphate homeostasis, has a similar function as SIK1 in protecting cells against toxic hypercalcium (Serlachius et al., 2002) and in regulating steroidogenesis in corpus luteal cells of the mammalian ovary (Paciga et al., 2003) . More recently, STC1 protein was showed higher expression in ovarian cancer tissues than in normal ovarian tissues, and overexpression of STC1 increased cell proliferation and colony formation in vitro and in vivo (Liu et al., 2010) . The molecular mechanisms underlying STC1-mediated ovarian tumorigenesis were characterized through inhibition of cell apoptosis and modulation of cell cycle regulatory proteins to promote cell growth. (40) Adenomyosis (20) 16 (80) 2 (10) Leiomyoma (20) 4 (20) 0 (0) Histological subtype of ovarian cancer (n ¼ 38) Serous (13) 12 (92.3) 11 (84.6) Non-serous (25) 19 (76) c 10 (40) c, *** Endometriod (8) 8 (100) 3 (37.5) Clear cell (6) 4 (66.7) 3 (50) Mucinous (3) 1 (33.3) 0 (0) Mixed (3) 2 (66.7) 0 (0) Others (5) d 4 (80) 4 (80) Stage of ovarian cancer (n ¼ 38) 
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However, the downstream signaling effectors of STC1 responsible for these biological outcomes are not defined yet. Interestingly, we herein demonstrated that the tumorigenic potency of SIK3 was mediated by a similar mechanism that upregulates gene expression of cyclin Ds and cyclin E. It also simultaneously downregulates p21 Waf/Cip1 and p27 Kip protein expression to accelerate G1/S progression, and permitted the cells to grow in mice. Subsequently, we further characterized the driving force mediated by SIK3 to facilitate the cell cycle progression using a pharmacological approach, and identified that c-Src was the downstream signaling mediator of SIK3. This finding is also indirectly supported by our IHC study, showing that c-Src was coexpressed with SIK3 in 84.6% of the SIK3-positive ovarian cancer samples. However, it is not clear how SIK3 serine/threonine kinase can phosphorylate the Tyr416 residue of c-Src. On the basis of our current data revealing that the c-Src phosphorylation event could be affected by treatment of Brefeldin A (unpublished data), we therefore speculate that the activation of c-Src by SIK3 may be through a secretory action, and wonder if STC1 may be a potential target gene downstream to SIK3. In spite of this assumption, we still cannot exclude a possibility that SIK3 may recruit other tyrosine kinases to phosphorylate c-Src because SIK3 possesses a proline-rich region located in its N-terminus.
SIK3 is an immunogenic target of the malignant ascitic antibodies of an ovarian cancer patient, and shows higher specificity to ovarian cancer than CA125. Unlike the tissue preferences of SIK1 and SIK2, SIK3 is ubiquitously distributed in a variety of tissues but with the lowest basal expression level found in ovarian tissue (data not shown). However, here we demonstrated that 55% of patients with ovarian cancers had SIK3 overexpression, and 70% of those patients were diagnosed as the late stages of this disease, suggesting that increasing expression of SIK3 is one of the common scenarios during tumor development and may be associated with the disease malignancy. In contrast to the specificity of CA125 to ovarian cancer (65%), the SIK3 immunoreactivity was either not or rarely found in normal ovarian tissue and benign diseases such as adenomyosis and leiomyoma, displaying 96.7% specificity to ovarian cancer in our cases. Despite SIK3 having a lower sensitivity to ovarian cancer than CA125, we suggest that the combined detection of SIK3 and CA125 may improve the specificity and success of ovarian cancer detection in clinical use. However, a larger cohort of patients with ovarian cancer and other cancer types such as brain, lung, breast, liver, colon and cervical cancers is still required to further define the SIK3 diagnostic specificity and prognostic values against ovarian cancers in future.
This study identified SIK3 as an ovarian TAA and for the first time reported that its overexpression was closely associated with ovarian cancers. Additionally, we also further elucidated the mechanisms involved in SIK3-mediated ovarian tumorigenesis. We believe that identification of TAAs including SIK3 is not only a crucial step in understanding their roles on a molecular basis in cancer immunology, but it also bestows both diagnostic and therapeutic advantages to clinical applications of ovarian cancers. 
Materials and methods
Additional methods and materials available from Supplementary Information Detailed description of screening for phage library for tumor-associated peptides, immunohistochemistry, statistics, northern blot analysis, gene construct and antiserum generation are available from the Supplementary Materials and methods.
Cells and cell culture SK-OV3 and OC109 cells were cultured in McCoy's 5A medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml)/ streptomycin (100 mg/ml), 0.1 mM non-essential amino acids, and 1 mM sodium pyruvate (Invitrogen). OVCAR3 cells were maintained in RPMI1640 (Invitrogen) containing 10% FBS. TOV-112D as well as IOSE385 cells were maintained in MCDB105 medium/medium 199 (1:1) (Sigma-Aldrich, St Louis, MO, USA) plus 15% FBS. HeLa cells were maintained in Dulbecco's modified Eagle's medium containing 10% FBS.
To generate cells with stable overexpression or attenuated expression of SIK3, OVCAR3 and SK-OV3 cells were transfected with the pcDNA-SIK3 plasmid and a plasmid transcribing SIK3-specific interfering small hairpin RNA (5 0 -CCG GGCCAGGCTTTATCTTATCAAACTCGAGTTTGATAAG ATAAAGCCTGGCTTTTTG-3 0 ) (Open Biosystems, Huntsville, AL, USA), respectively. Simultaneously, their corresponding control cells were also established by transfection of either pcDNA3.1 or pLKO.1 vector and selection in the medium containing 400 mg/ml of G418 or 2.5 mg/ml of puromycin, respectively. After limiting dilution, the expression levels of individual cell clones were confirmed by immunoblotting analyses.
Ascitic fluids, sera and tissue samples Twelve malignant ascitic fluid samples were obtained from ovarian cancer patients with 10 serous, 1 mucinous and 1 cystadenocarcinoma subtypes. Paraffin-embedded tissue samples were collected with the permission of the Institution Review Board of the Taipei Medical University. The samples included 20 adenomyosis, 20 leiomyoma, 20 normal ovary and 38 ovarian cancer samples. The histological subtypes of the ovarian cancers included 13 serous, 8 endometrioid, 6 clear cell, 3 mucinous, 3 endometrioid/clear cell mixed subtypes and 5 poorly differentiated samples. Normal ovarian tissues were obtained from patients who received total hysterectomy and oophorectomy without ovarian lesions. Control serum samples were obtained from 10 age-matched healthy women. The IgG fractions of the ascitic fluids and control serum samples were purified with Protein A/G (Thermo Fisher, Rockford, IL, USA), according to the manufacturer's instructions.
Western blot analysis
Cell lysates were prepared as previously described (Chang et al., 2006) . Briefly, cells were transfected with plasmids using Lipofectamine for HeLa cells, Lipo2000 (Invitrogen) for SK-OV3, and ExGene 500 (Fermentas, Vilnius, Lithuania) for OVCAR3 cells. After transfection, cells were treated with or without various pharmacological inhibitors such as LY294002 for PI3K, PD98059 for mitogen-activated protein/ extracellular signal-regulated kinase 1, rapamycin for mechanistic target of rapamycin-mediated S6 kinase, staurosporine for broad-spectrum protein kinases, H89 for protein kinase A and PP2 for Src-family tyrosine kinases. Afterward, the cells were lyzed in cell lysis buffer (Chang et al., 2006) , and the protein concentration was quantified using the BCA assay (Thermo Fisher). The lysates were resolved in 7.5-10% polyacrylamide gel containing sodium dodecyl sulfate, transferred to nitrocellulose membranes, and probed with purified CA502 ascitic antibody (32 mg/ml) or antibody specific to Myc tag, GST-tag (Thermo Fisher), p21 Waf/Cip1 , p27
Kip , cyclin Ds, cyclin E, pTyr 416 -Src, c-Src (Cell Signaling Technology, Beverly, MA, USA) or SIK3. For detection of CRBN expression in ovarian cancer cells, GST-CRBN recombinant protein and CRBN antibody were purchased from Abnova Co. (Taipei, Taiwan). b-Actin served as a protein loading control. The immunocomplexes were detected by probing with anti-mouse, -rabbit or -human IgG conjugated with horseradish peroxidase (Jackson ImmunoResearch, Cambridgeshire, UK), and were visualized using the SuperSignal detection system (Thermo Fisher).
Cell growth assay
The parental and stably transfected cells (2 Â 10 4 cells per well) were seeded in 24-well plates and incubated for 24, 48, 72 or 96 h ( Figure 2B ). Cells (3 Â 10 4 cells per well) were incubated for 24 h and followed by PP2 treatment for 24, 48 or 72 h in Figure 5c . Cell proliferation was determined by incubating the cells with 200 ml of fresh medium containing 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) for 4 h at 37 1C. After removal of the MTT solution, the resulting formazan crystals were dissolved completely in an ethanol/dimethyl sulfoxide mixture (1:1) and quantified using an enzyme-linked immunosorbent assay plate reader (Metertech 960, Metertech Inc., Taipei, Taiwan) by measuring the absorbance at 550 nm. Triplicate wells were assayed for each experiment and three independent experiments were performed. Data are expressed as the mean of OD 550 ± s.d.
Clonogenic assay
The SIK3 stable transfectants (clone ov-21) and control cells were seeded in six-well culture plates at 250, 500 or 1000 cells per well in triplicate. Cells were maintained in culture for 9 days, with medium change every 3 days, to let the viable cells propagate to sizable colonies. After phosphate-buffered saline wash, the cells were stained with methylene blue (USB, Cleveland, OH, USA) for 2 h in room temperature and photographed under a microscopy. After cell lysis in 200 ml of 1% Lauroylsarcosine solution (Sigma-Aldrich) per well, the dye was released and transferred to a new 96-well plate. The concentrations of individual wells were quantified using SpectraMax M5 ELISA plate reader (Molecular Devices, Sunnyvale, CA, USA) by measuring the absorbance at 550 nm. Data are expressed as the mean of OD 550 ±s.d.
Cell cycle analysis
For synchronization of the cell cycle, stable transfectants (1 Â 10 5 per well) were seeded in six-well plates and incubated in media supplemented with 0.1% FBS for 24 h. Subsequently, the cells were incubated with 10% FBS-containing fresh medium for 6 h. For transient transfection experiments, cells (1 Â 10 5 per well) were seeded, incubated overnight, and transfected with 1 or 2 mg of expression plasmids to overexpress SIK3 or c-Src or with interfering small hairpin RNA plasmids to knockdown SIK3, c-Src or p21
Waf/Cip1 expression, as indicated in the figure legends of Figures 4 and 7 , for 48 h. After being trypsinized, washed with phosphate-buffered saline twice and fixed with 70% cold ethanol, the cells were collected by centrifugation at 5000 Â g for 5 min, and then
